Marker Therapeutics Stock (NASDAQ:MRKR)
Previous Close
$3.19
52W Range
$2.44 - $6.16
50D Avg
$3.29
200D Avg
$4.00
Market Cap
$28.38M
Avg Vol (3M)
$34.69K
Beta
1.49
Div Yield
-
MRKR Company Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
MRKR Performance
Peer Comparison
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
IKNA | Ikena Oncology, Inc. |
XCUR | Exicure, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
ALEC | Alector, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
KROS | Keros Therapeutics, Inc. |
AGEN | Agenus Inc. |
RNXT | RenovoRx, Inc. |
TPST | Tempest Therapeutics, Inc. |
BNOX | Bionomics Limited |
ANEB | Anebulo Pharmaceuticals, Inc. |
PTIX | Protagenic Therapeutics, Inc. |
CBIO | Gyre Therapeutics, Inc. |
AADI | Aadi Bioscience, Inc. |
LUMO | Lumos Pharma, Inc. |